Proc. roy. Soc. Med. Volume 70 March 1977 Medical Advisers in the Pharmaceutical Industry (AMAPI) in 1975, held in Florence, and further details of our approach to identifying drug action in human volunteers were discussed by my colleague Dr T J Sullivan (Sullivan & Fell, Proceedings of the Second International Meeting of Medical Advisers in the Pharmaceutical Industry. Excerpta Medica, Amsterdam; pp 229-232). We believe that considerable progress will be made in drug discovery by approaches along these lines, although of course there are drug actions which at the present time we have no means ofdemonstrating in normal human volunteers.
It is unfortunate that no mention was made of the collaboration between universities and drug companies. I doubt whether my own company could operate effectively without the excellent twoway collaboration we have with many university departments and research institutes throughout the world. However, it would certainly be mutually beneficial to increase even further the collaboration between universities and the pharmaceutical industry as Professor Bisset suggested, and particularly to encourage the interchange of research workers between the industry and the universities.
Clinical pharmacology departments are developing within the industry, both to undertake clinical research and as part of drug development. We have participated in a training scheme for medical graduates in clinical pharmacology whereby the trainee spends part of the time at medical schools in London and Nottingham University and part of the time in our clinical pharmacology unit. This scheme is still at an early stage, but hopefully this may lead to some of the advantages suggested by Professor Bisset. Similar proposals for postdoctoral fellowships in pharmacology are also under discussion as well as exchange of scientists in the field of toxicology and safety evaluation. However, together with many of my colleagues in the industry, I would welcome further suggestions which would encourage growth in this vital field of collaboration. Yours sincerely J S G COX 7 January 1977 Dear Sir, I agree with Professor Bisset that there are three main approaches to the development of new drugs in the pharmaceutical industry: the empirical, the rational and serendipity. In this company we seek wherever possible a balance between rational design and empiricism, and certainly our chemists strive to be rational in the design of new molecules. However in certain areas of research the rational approach sometimes proves to be extremely difficult and one is forced back to empiricism. I am sure that most research scientists would agree about the undesirability of 'me too' drugs, but on many occasions minor modifications in chemical structure result in major qualitative differences, and as Dr Cromie pointed out in the discussion at the Medico-Pharmaceutical Forum it is sometimes a series of smaller leaps which produce therapeutic benefit which would never have come about if premarketing selection had been allowed as recommended by Dr Herxheimer.
Professor Bisset is right to suggest a need for close collaboration between pharmaceutical companies and universities. I did of course refer in my paper to 'the possibility of collaboration between bodies such as the MRC and the pharmaceutical industry', and such collaboration was also referred to in various contributions from the floor during the forum. I am sure that most companies would welcome closer collaboration with university departments, particularly those with areas of special expertise of interest to individual industrial research departments. There is certainly very close collaboration when we reach the stage of introducing drugs into the clinic, and I should also like to record the use of the Science Research Council's CASE Award Scheme (Cooperative Awards in Science and Engineering) which is a useful means of furthering this cooperation. In my experience these awards strengthen the bond between industry and universities. Currently this company has four CASE awards plus an additional one which is due to start from October 1977. Yours faithfully P T MAIN
